Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
Provided By GlobeNewswire
Last update: Jul 23, 2025
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.
Read more at globenewswire.com
